logo

News

Bioiberica Farma inaugurates Online Newsroom

Pharmaceutical company Bioiberica Farma places at the disposal of the journalist community complete information about the company’s operations, up-to-date news and the latest trends in osteoarthritis.
The ‘Osteoarthritis Agenda’ section will list the most important congresses dealing with this disease, such as the World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases that is going to be held the coming 20th of January.

Between 15 and 20 per cent of psoriasis patients develop psoriatic osteoarthritis

‘Beneath the skin’
Conference on psoriatic osteoarthritis and other chronic inflammatory diseases

One out of every seven consultations with family physicians are for osteoarthritis

This rheumatic disease affects 24% of Spaniards aged 45 and older
It is estimated that by 2020 osteoarthritis will become the fourth most common cause of disability because of the population’ longer life expectancy and progressive ageing.
Apart from ageing, the other factors leading to the development of osteoarthritis are obesity, genetic predisposition and joint overuse.
The role of family physicians is fundamental in the early detection of osteoarthritis because they are the medicine professionals most frequently consulted by the general population.

29% of Football Players, at risk of Developing Knee Osteoarthritis

Elite competition, injuries and joint overuse, among the major risk factors that may end up causing osteoarthritis.

Dr. Villalón, head of the Club Atlético de Madrid medical department, points out that the chances of a sportsperson of developing osteoarthritis increase after suffering a knee trauma.

“Chondroprotection” would be the array of measures aiming at preventing, delaying, stabilizing, repairing and even completely eliminating the damage caused by osteoarthritis.

Bioiberica Farma leads a new clinical essay to test the efficacy and security of the combination of chondroitin sulfate and glucosamine

MOVES is a new multicenter clinical essay involving 560 patients from Spain, Germany, France and Poland.

The aim of the MOVES project (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) is to contribute further evidence of the efficacy and security of the combination of chondroitin sulfate and glucosamine in the treatment of knee osteoarthritis patients with moderate to severe pain.

Launched the first SEMERGEN guidelines for the management of osteoarthritis. These clinical guidelines are largely directed at primary care physicians

Osteoarthritis causes 35% of primary care visits

Primary care physicians should play a key role in the diagnosis and treatment of osteoarthritis in order to improve its symptoms (pain, functional disability) and to delay its progression

Eight out of every ten menopausal women suffer from joint pain

The decrease in estrogen levels caused by the arrival of menopause is one of the risk factors for the development of osteoarthritis.

Gynecologists are now beginning to diagnose and treat post menopausal osteoarthritis.

Osteoarthritis in menopausal women is under diagnosed, and affects negatively their quality of life.

semFYC and Bioibérica Farma join forces to boost the Programa de Actividades Comunitarias en Atención Primaria (PACAP)

* Scientific and educational activities and the dissemination of information on communal activities will be the two main pillars of the agreement.

* The objectives of the PACAP are to encourage healthy lifestyles, disseminate information related to health issues, and to improve the quality of life and the social welfare level of the population.

“We are astonished at the current lack of attention to osteoarthritis”. Correo Farmacéutico interviews Josep Escaich

The general manager of Bioiberica highlighted his company’s commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients’ quality of life.

Dr. Josep Vergés, medical and scientific director of BIOIBERICA, appeared on the TVE program “Saber Vivir”

The “La mañana de la 1” program, broadcast by Televisión Española (TVE), devoted its “saber vivir” health section to the treatment of osteoarthritis.


Any doubt?
Contact us and we will write
you as soon as posible.

Contact